Onsdag 17 September | 22:28:28 Europe / Stockholm

Prenumeration

Kalender

Est. tid*
2026-05-07 N/A Årsstämma
2026-05-07 08:30 Kvartalsrapport 2026-Q1
2026-02-20 08:30 Bokslutskommuniké 2025
2025-10-30 08:30 Kvartalsrapport 2025-Q3
2025-10-10 N/A Extra Bolagsstämma 2025
2025-08-11 - Kvartalsrapport 2025-Q2
2025-05-08 - X-dag ordinarie utdelning LUMITO 0.00 SEK
2025-05-07 - Årsstämma
2025-05-07 - Kvartalsrapport 2025-Q1
2025-02-20 - Bokslutskommuniké 2024
2024-10-31 - Kvartalsrapport 2024-Q3
2024-08-23 - Kvartalsrapport 2024-Q2
2024-05-08 - X-dag ordinarie utdelning LUMITO 0.00 SEK
2024-05-07 - Årsstämma
2024-05-07 - Kvartalsrapport 2024-Q1
2024-02-22 - Bokslutskommuniké 2023
2023-10-31 - Kvartalsrapport 2023-Q3
2023-08-17 - Kvartalsrapport 2023-Q2
2023-05-26 - X-dag ordinarie utdelning LUMITO 0.00 SEK
2023-05-25 - Årsstämma
2023-05-03 - Kvartalsrapport 2023-Q1
2023-02-23 - Bokslutskommuniké 2022
2022-11-02 - Kvartalsrapport 2022-Q3
2022-08-18 - Kvartalsrapport 2022-Q2
2022-05-30 - X-dag ordinarie utdelning LUMITO 0.00 SEK
2022-05-27 - Årsstämma
2022-05-06 - Kvartalsrapport 2022-Q1
2022-02-17 - Bokslutskommuniké 2021
2021-11-24 - Extra Bolagsstämma 2021
2021-10-20 - Kvartalsrapport 2021-Q3
2021-08-18 - Kvartalsrapport 2021-Q2
2021-05-28 - X-dag ordinarie utdelning LUMITO 0.00 SEK
2021-05-27 - Årsstämma
2021-04-28 - Kvartalsrapport 2021-Q1
2021-02-17 - Bokslutskommuniké 2020
2020-11-03 - Kvartalsrapport 2020-Q3
2020-08-20 - Kvartalsrapport 2020-Q2
2020-05-28 - X-dag ordinarie utdelning LUMITO 0.00 SEK
2020-05-27 - Årsstämma
2020-04-28 - Kvartalsrapport 2020-Q1
2020-02-17 - Bokslutskommuniké 2019
2019-10-31 - Kvartalsrapport 2019-Q3
2019-08-21 - Kvartalsrapport 2019-Q2
2019-06-04 - Årsstämma
2019-05-23 - X-dag ordinarie utdelning LUMITO 0.00 SEK
2019-04-30 - Kvartalsrapport 2019-Q1
2019-02-15 - Bokslutskommuniké 2018

Beskrivning

LandSverige
ListaNordic SME Sweden
SektorHälsovård
IndustriMedicinteknik
Lumito specialiserar sig på medicinsk teknik för digital patologi. Bolaget strävar efter att förbättra vävnadsdiagnostiken med sin patenterade teknologi baserad på uppkonverterade nanopartiklar. Bolaget planerar att initialt lansera sin första produkt för forskningslaboratorier. Bolaget bildades under 2010 som en spinoff från en forskargrupp vid Lunds universitets avdelning för atomfysik och lasercentrum. Lumito har sitt huvudkontor i Lund.
2025-09-10 08:30:00

Lumito has become a new partner in “Biobarriers – Health, Disorders and Healing”, a government-funded project focusing on the development of new technologies to improve health, as well as diagnostics and treatments. This research and collaboration initiative focuses on the body’s biological barriers, such as skin and mucous membranes in, for example, the gastrointestinal tract. The partnership strengthens Lumito's position in advanced tissue imaging and opens new opportunities for continued technology development and commercial growth.

Biobarriers is funded by the Knowledge Foundation (KK-stiftelsen), which supports applied research with clear commercial potential. Led by Malmö University, the project brings together leading actors from both academia and industry. For Lumito, the collaboration offers a unique opportunity to contribute to the diagnostics and treatments of the future, while simultaneously strengthening the company’s commercial opportunities and networks.

Lumito will contribute its expertise in digital tissue imaging and biomarker quantification, while also benefitting from access to relevant research environments, strategic collaborations and opportunities to further develop its technology in market-relevant applications.

“Lumito has a unique technology that our researchers need to identify individual cells in tissues. Understanding how these cells affect the health of biological barriers is crucial – not only for our research, but also for the companies involved in the project. The Biobarriers consortium looks forward to an exciting and fruitful collaboration with Lumito,” says Johan Engblom, Professor and Project Leader at Malmö University.
“We are pleased to be accepted as a partner in the Biobarriers project. It gives us the opportunity to contribute with our technology to the project's goals and to collaborate closely with researchers and industry partners. Through this partnership, we can jointly develop new solutions to improve health and drug development, which is fully in line with our strategy to build relevance and create long-term value within advanced tissue imaging,” says Sanna Wallenborg, CEO of Lumito.

Lumito has already contributed to the project through its ongoing collaboration with Professor Håkan Eriksson and doctoral researcher Sylwia Hasterok at Malmö University, work which has already been communicated earlier this year through results and presentations.

The project runs from 2019 to 2028 and brings together an extensive network of researchers and companies within life sciences. Through this partnership, Lumito strengthens its position in establishing SCIZYS as a relevant and in-demand technology in both research and drug development.

Further information about the Biobarriers project can be found on Malmö University’s website.